[go: up one dir, main page]

WO2018186650A3 - Comprimé composite double pour administration orale contenant du tramadol et du célécoxib - Google Patents

Comprimé composite double pour administration orale contenant du tramadol et du célécoxib Download PDF

Info

Publication number
WO2018186650A3
WO2018186650A3 PCT/KR2018/003905 KR2018003905W WO2018186650A3 WO 2018186650 A3 WO2018186650 A3 WO 2018186650A3 KR 2018003905 W KR2018003905 W KR 2018003905W WO 2018186650 A3 WO2018186650 A3 WO 2018186650A3
Authority
WO
WIPO (PCT)
Prior art keywords
pain
celecoxib
tramadol
alleviation
symptoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2018/003905
Other languages
English (en)
Korean (ko)
Other versions
WO2018186650A2 (fr
Inventor
김승현
황성주
안준현
현상민
곽상원
선보경
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kims Healthcare Co Ltd
Industry Academic Cooperation Foundation of Yonsei University
Original Assignee
Kims Healthcare Co Ltd
Industry Academic Cooperation Foundation of Yonsei University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kims Healthcare Co Ltd, Industry Academic Cooperation Foundation of Yonsei University filed Critical Kims Healthcare Co Ltd
Priority to US16/500,311 priority Critical patent/US20200323780A1/en
Priority claimed from KR1020180038579A external-priority patent/KR102033716B1/ko
Publication of WO2018186650A2 publication Critical patent/WO2018186650A2/fr
Publication of WO2018186650A3 publication Critical patent/WO2018186650A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un comprimé composite double pour administration orale, comprenant : une couche à libération prolongée contenant du tramadol en tant que principe actif; et une couche à libération immédiate contenant du célécoxib en tant que principe actif, le comprimé composite double étant une préparation orale qui est prescrite pour soulager les symptômes ou les signes de l'arthrose (arthrite dégénérative), de la polyarthrite rhumatoïde, de la spondylarthrite ankylosante, pour soulager la douleur aiguë chez l'adulte (douleur post-opératoire ou post-extraction), la dysménorrhée primaire, ou la douleur aiguë ou chronique sévère et modérée. Grâce à la présente invention, on peut donc obtenir une composition pour le traitement de la douleur qui réduit les effets secondaires du tramadol et a un effet antidouleur continu pendant 12 heures par libération prolongée de tramadol soluble dans l'eau et libération immédiate de célécoxib peu soluble. En outre, le nombre de médicaments administrés diminue grâce à l'intégration de deux types de médicaments dans une seule préparation complexe, ce qui permet d'améliorer la commodité d'administration de ces médicaments.
PCT/KR2018/003905 2017-04-03 2018-04-03 Comprimé composite double pour administration orale contenant du tramadol et du célécoxib Ceased WO2018186650A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/500,311 US20200323780A1 (en) 2017-04-03 2018-04-03 Bilayer combination tablet for oral administration containing tramadol and celecoxib

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2017-0042927 2017-04-03
KR20170042927 2017-04-03
KR1020180038579A KR102033716B1 (ko) 2017-04-03 2018-04-03 트라마돌과 셀레콕시브를 포함한 경구투여용 이중 복합정제
KR10-2018-0038579 2018-04-03

Publications (2)

Publication Number Publication Date
WO2018186650A2 WO2018186650A2 (fr) 2018-10-11
WO2018186650A3 true WO2018186650A3 (fr) 2019-01-03

Family

ID=63712189

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/003905 Ceased WO2018186650A2 (fr) 2017-04-03 2018-04-03 Comprimé composite double pour administration orale contenant du tramadol et du célécoxib

Country Status (1)

Country Link
WO (1) WO2018186650A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113521292A (zh) * 2020-04-15 2021-10-22 江苏恒瑞医药股份有限公司 一种cox-2抑制剂和曲马多的复方制剂

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120089287A (ko) * 2009-10-16 2012-08-09 라보라토리오스 델 드라. 에스테브.에스.에이. 통증 치료에 있어서 트라마돌 및 셀레콕시브를 포함하는 조성물
KR101710792B1 (ko) * 2015-07-14 2017-02-28 주식회사 유영제약 세레콕시브 및 트라마돌을 함유하는 약제학적 조성물

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120089287A (ko) * 2009-10-16 2012-08-09 라보라토리오스 델 드라. 에스테브.에스.에이. 통증 치료에 있어서 트라마돌 및 셀레콕시브를 포함하는 조성물
KR101710792B1 (ko) * 2015-07-14 2017-02-28 주식회사 유영제약 세레콕시브 및 트라마돌을 함유하는 약제학적 조성물

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KODAM, DEEPTHI ET AL.: "Formulation and Evaluation of Tramadol Hydrochloride Sustained Matrix Tablets", SCHOLARS RESEARCH LIBRARY, DER PHARMACIO LETTER, vol. 3, no. 3, 2011, pages 245 - 249, XP055560093 *
RAO, P. SAMBA SIVA ET AL.: "Formulation and Evaluation of Tramadol Hcl Sustained Released Pellets", INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACY AND CHEMISTRY, vol. 5, no. 3, 2015, pages 413 - 419, XP055560101 *
REHMAN, ASIM.UR ET AL.: "Formulation and Evaluation of Tramadol HCL Matrix Tablets Using Carbopol 974P and 934 as Rate-controlling Agents", TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, vol. 12, no. 2, 2013, pages 169 - 172, XP055560103 *

Also Published As

Publication number Publication date
WO2018186650A2 (fr) 2018-10-11

Similar Documents

Publication Publication Date Title
PH12015502134B1 (en) Mosapride sustained-release formulation providing pharmacological and clinical effects with once-daily administration
EA201690102A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
HRP20210618T1 (hr) Povećavanje bioraspoloživosti lijeka u terapiji naltreksonom
NZ595467A (en) Sublingual pharmaceutical composition comprising a neutral oil
WO2014144407A8 (fr) Comprimés de composition pharmaceutique orale à double utilisation de sels de sulfate et leurs procédés d'utilisation
WO2010098627A3 (fr) Préparation pharmaceutique
PH12015501377A1 (en) Solid unit with high fexofenadine content and process for the preparation thereof
AU2018282104A1 (en) Use of vibegron to treat overactive bladder
WO2012035561A3 (fr) Système amélioré d'administration ciblée de médicaments par voie orale
HRP20190891T1 (hr) Medicinski proizvod i tretman
WO2018186650A3 (fr) Comprimé composite double pour administration orale contenant du tramadol et du célécoxib
JP2012505830A5 (fr)
WO2012042197A3 (fr) Composition pharmaceutique faiblement dosée
PH12014502836B1 (en) Medicament form for release of active ingredients
MX2022013541A (es) Composiciones de acido gamma-poliglutamico y zinc.
IL300144A (en) Benzazepines are combined for the treatment of Tourette syndrome
JP2019529559A5 (fr)
MY187270A (en) Renal insufficiency progression inhibitor, prophylactic agent for renal insufficiency and indoxyl sulfate production inhibitor
WO2020190900A8 (fr) Formulations pharmaceutiques à base d'abiratérone et d'oligomère cyclique et procédés de formation et d'administration de celles-ci
WO2015166419A3 (fr) Procédé d'obtention et composition pharmaceutique de kétorolac trométhamine et de chlorhydrate de tramadol à administration sublinguale pour soulager la douleur
WO2011108882A3 (fr) Composition pharmaceutique pour la prévention ou le traitement de l'ostéoarthrite contenant du rébamipide en tant que principe actif
CN102949383A (zh) 一种抗炎镇痛的药物组合物
MX386908B (es) Formulacion de liberacion modificada de naproxeno sodico.
MXPA06000760A (es) Composicion farmaceutica estable de carisoprodol y meloxicam.
MX2017009660A (es) Composicion farmaceutica con un rango de relacion entre el clorhidrato de tramadol y el etoricoxib para su administracion para el tratamiento del dolor.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18780409

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18780409

Country of ref document: EP

Kind code of ref document: A2